All In Biotech

Drug Trial Radar · NCT05000450

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-647 and ALLO-605, an Anti- BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Jun 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

6

Actual

Start

Jun 6, 2021

Primary completion

Oct 11, 2023

Study completion Oct 11, 2023

Sponsor

Lead sponsor
Allogene TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the ALLO-605-201 study is to assess the safety, efficacy, and cell kinetics of ALLO605 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.

Conditions

  • Relapsed/Refractory Multiple Myeloma

Interventions

  • ALLO-605Genetic

    ALLO-605 is an anti-BCMA, TRAC/CD52 allogeneic edited, intracellular cytokine signaling containing, CAR T cell product

  • ALLO-647Biological

    ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

  • FludarabineDrug

    Chemotherapy for lymphodepletion

  • CyclophosphamideDrug

    Chemotherapy for lymphodepletion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-605 that will determine MTD/MAD and select the recommended Phase 2 dose (RP2D) of ALLO-605.Time frame: 28 days
  2. Phase 1: Proportion of patients experiencing Dose Limiting Toxicities with ALLO-647 [administered in combination with fludarabine/cyclophosphamide administered prior to ALLO-605]Time frame: 30 days
  3. Phase 2: To assess clinical efficacy of ALLO-605 as measured by overall response rate (ORR)Time frame: 12 months of study follow-up

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Sarah Cannon/Colorado Blood Cancer Institute

    Denver, Colorado

  • St. David's South Austin Medical Center

    Austin, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Texas Transplant Institute

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.